Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.
Lalama CM, Jennings C, Johnson VA, Coombs RW, McKinnon JE, Bremer JW, Cobb BR, Cloherty GA, Mellors JW, Ribaudo HJ; AIDS Clinical Trials Group. Lalama CM, et al. Among authors: mckinnon je. J Clin Microbiol. 2015 Aug;53(8):2659-66. doi: 10.1128/JCM.00801-15. Epub 2015 Jun 10. J Clin Microbiol. 2015. PMID: 26063861 Free PMC article.
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW. Cillo AR, et al. Among authors: mckinnon je. AIDS. 2015 Oct 23;29(16):2121-9. doi: 10.1097/QAD.0000000000000810. AIDS. 2015. PMID: 26544577 Free PMC article. Clinical Trial.
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. Wilkin TJ, et al. J Infect Dis. 2012 Aug 15;206(4):534-42. doi: 10.1093/infdis/jis376. Epub 2012 Jun 27. J Infect Dis. 2012. PMID: 22740718 Free PMC article. Clinical Trial.
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
McKinnon JE, Mailliard RB, Swindells S, Wilkin TJ, Borowski L, Roper JM, Bastow B, Kearney M, Wiegand A, Mellors JW, Rinaldo CR; A5201 study team. McKinnon JE, et al. PLoS One. 2014 May 6;9(5):e95524. doi: 10.1371/journal.pone.0095524. eCollection 2014. PLoS One. 2014. PMID: 24802242 Free PMC article. Clinical Trial.
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, Swindells S. Wilkin TJ, et al. Among authors: mckinnon je. J Infect Dis. 2009 Mar 15;199(6):866-71. doi: 10.1086/597119. J Infect Dis. 2009. PMID: 19191590 Free PMC article. Clinical Trial.
35 results